恶性肿瘤患者新冠病毒疫苗接种的专家意见

doi:10.19871/j.cnki.xfcrbzz.2022.02.001

新发传染病电子杂志 ›› 2022, Vol. 7 ›› Issue (2): 1-5.doi: 10.19871/j.cnki.xfcrbzz.2022.02.001

• 新型冠状病毒肺炎防治专题 • 下一篇

恶性肿瘤患者新冠病毒疫苗接种的专家意见

袁静¹, 谭晓华¹, 王福祥¹, 王绿化², 卢洪洲¹

1.深圳市第三人民医院,广东深圳 518112;
2.中国医学科学院肿瘤医院深圳医院,广东深圳 518172

收稿日期:2022-04-30 出版日期:2022-05-31 发布日期:2022-07-07
通讯作者: 卢洪洲,Email：luhongzhou@fudan.edu.cn
基金资助:
1.国家自然科学基金（32001038）; 2.“十四五”国家重点研发计划（2021YFC2301803）; 3.广东省高水平临床重点专科深圳市配套建设经费（SZGSP011）; 4.深圳市科技创新委员会抗疫专项(JSGG20220301090005007); 5.深圳市第三人民院院内课题(G2021027）

Expert advice on novel coronavirus vaccination in patients with malignant tumors

Yuan Jing¹, Tan Xiaohua¹, Wang Fuxiang¹, Wang Lyuhua², Lu Hongzhou¹

1. The Third People's Hospital of Shenzhen, Guangdong Shenzhen 518112,China;
2. Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Guangdong Shenzhen 518172, China

Received:2022-04-30 Online:2022-05-31 Published:2022-07-07

摘要/Abstract

摘要： 新型冠状病毒感染肆虐全球,有效的新冠病毒疫苗接种不仅可以降低新型冠状病毒的感染率,同时也可以降低感染后的疾病严重程度及病死率。有效的疫苗接种对免疫抑制人群尤为重要,但目前国内对恶性肿瘤患者新冠病毒疫苗接种的有效性和安全性认识仍然不足,导致该类人群疫苗接种率低。因此,基于恶性肿瘤患者接种新冠病毒疫苗的国内外研究进展和临床治疗需求,特制订此专家意见。本文将全面依据恶性肿瘤患者的肿瘤种类、抗癌治疗方案和阶段以及病情等复杂因素,详细提出该类人群的新冠病毒疫苗接种建议,以提高恶性肿瘤患者的新冠病毒疫苗接种率,有效保护恶性肿瘤患者,降低其因新型冠状病毒所致的感染率、重症率、死亡率。

关键词: 恶性肿瘤, 新型冠状病毒, 疫苗接种, 专家意见

Abstract: Since SARS-CoV-2 infection remains to be a global pandemic, effective vaccination strategies were urgent to reduce the infection rate of SARS-CoV-2, attenuate the progress of the disease, and decrease the mortality after infection, which is particularly important for immunosuppressed patients. However, the efficacy and safety of SARS-CoV-2 vaccination in patients with malignant tumor are not well investigated in China, therefore, leading to a low SARS-CoV-2 vaccination coverage in patients with malignant tumor. According to the most recent researches and clinical treatment demands of SARS-CoV-2 vaccination for patients with malignant tumors, we summarized a detailed SARS-CoV-2 vaccination regimen for malignant tumors patients with different types of tumor, distinct anticancer treatment plan, as well as specialized the disease condition, so as to improve SARS-CoV-2 vaccines coverage, effectively protect patients, and reduce the susceptibility, severity and mortality of SARS-CoV-2 infection in patients with malignant tumors.

Key words: Malignant tumor, Severe acute respiratory syndrome coronavirus 2, Vaccination, Expert advice

袁静, 谭晓华, 王福祥, 王绿化, 卢洪洲. 恶性肿瘤患者新冠病毒疫苗接种的专家意见[J]. 新发传染病电子杂志, 2022, 7(2): 1-5.

Yuan Jing, Tan Xiaohua, Wang Fuxiang, Wang Lyuhua, Lu Hongzhou. Expert advice on novel coronavirus vaccination in patients with malignant tumors[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(2): 1-5.

参考文献

[1] 郝鹏飞,许汪,杜寿文,等.冠状病毒起源、受体及新型冠状病毒检测与疫苗最新研究进展[J/CD].新发传染病电子杂志,2020,5(2):74-78.
[2] 李倩,卢洪洲.新型冠状病毒疫苗研究最新进展[J/CD].新发传染病电子杂志,2020,5(4):268-273.
[3] SUNG H, FERLAY J, SIEGEL RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin, 2021, 71(3):209-249.
[4] LIANG W, GUAN W, CHEN R, et al.Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21: 335-337.
[5] COREY L, BEYRER C, COHEN MS, et al.SARS-CoV-2 variants in patients with immunosuppression[J]. N Engl J Med, 2021, 385(6):562-566.
[6] DAI M, LIU D, LIU M, et al.Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak[J]. Cancer Discov, 2020, 10(6):783-791.
[7] SHAH V, KOKO T, ZUCKERMAN M, et al.Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience[J]. Br J Haematol, 2020, 190(5):e279-e282.
[8] YANG K, SHENG Y, HUANG C, et al.Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study[J]. Lancet Oncol, 2020, 21(7):904-913.
[9] ROBILOTTI EV, BABADY NE, MEAD PA, et al.Determinants of COVID-19 disease severity in patients with cancer[J]. Nat Med, 2020, 26(8):1218-1223.
[10] GIANNAKOULIS VG, PAPOUTSI E, SIEMPOS, II.Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data[J]. JCO Glob Oncol, 2020, 6:799-808.
[11] KUDERER NM, CHOUEIRI TK, SHAH DP, et al.Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study[J]. Lancet, 2020, 395(10241):1907-1918.
[12] BERTUZZI AF, CICCARELLI M, MARRARI A, et al.Impact of active cancer on COVID-19 survival: a matched-analysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy[J]. Br J Cancer, 2021, 125(3):358-365.
[13] WU JT, LA J, BRANCH-ELLIMAN W, et al.Association of COVID-19 Vaccination With SARS-CoV-2 Infection Patients With Cancer: A US Nationwide Veterans Affairs Study[J]. JAMA Oncol, 2022, 8(2):281-286.
[14] THAKKAR A, GONZALEZ-LUGO JD, GORADIA N, et al.Seroconversion rates following COVID-19 vaccination among patients with cancer[J]. Cancer Cell, 2021, 39(8):1081-1090.
[15] HERISHANU Y, AVIVI I, AHARON A, et al.Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia[J]. Blood, 2021, 137(23):3165-3173.
[16] GRANNIS SJ, ROWLEY EA, ONG TC, et al.Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2B.1.617.2(Delta) Variant Predominance-Nine States, June-August 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(37):1291-1293.
[17] 廖康生,卢洪洲.新型冠状病毒奥密克戎变异株的研究进展:对其科学防控措施的启示[J/CD].新发传染病电子杂志,2022,7(1):1-5.
[18] 中华人民共和国国家卫生健康委员会疾病预防控制局. 新冠病毒疫苗接种技术指南(第一版)[J].中国病毒病杂志, 2021, 11(3):161-162.
[19] 徐若男,聂建云,王涛, 等. 乳腺癌患者新冠疫苗接种中国专家共识[J]. 传染病信息, 2021, 34(6):481-484.
[20] NATIONAL COMPREHENSIVE CANCER NETWORK. Cancer and COVID-19 Vaccination (V6.0)[EB/OL]. [2022-04-27].https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v5-0.pdf?sfvrsn=b483da2b_114.
[21] EUROPEAN CANCER PATIENT COALITION. 癌症病人新冠疫苗接种指南(中文版)[EB/OL]. https://ecpc.org/news-events/癌症病人新冠疫苗接种指南(中文版).
[22] DESAI A, GAINOR JF, HEGDE A, et al.COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials[J]. Nat Rev Clin Oncol, 2021, 18(5):313-319.
[23] VIVEK N, KERRI JS, EVAN CL, et al.Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer[J]. Cancer Cell, 2022, 40(1):103-108.
[24] 张哲,马莹,董妥,等. 新型冠状病毒变异株对新冠病毒疫苗免疫效力的影响[J]. 国际免疫学杂志,2021, 44(5): 487-492.
[25] NATIONAL COMPREHENSIVE CANCER NETWORK. COVID-19 resources[EB/OL].[2021-11-19]. https://www.nccn.org/covid-19.
[26] AMERICAN SOCIETY OF HEMATOLOGY. ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients: frequently asked questions[EB/OL].[2021-11-20]. https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients.
[27] AMERICAN SOCIETY OF HEMATOLOGY. General principles of COVID-19 vaccines for immunocompromised patients[EB/OL].[2021-12-24].https://www.hematology.org/covid-19.

恶性肿瘤患者新冠病毒疫苗接种的专家意见

Expert advice on novel coronavirus vaccination in patients with malignant tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘文浩, 杨金荣, 陈一鑫, 周昀, 李银凤, 云永兴, 杨根东, 黄华. 新型冠状病毒奥密克戎变异株感染：普通型与无症状/轻型的临床特征比较分析及胸部CT表现[J]. 新发传染病电子杂志, 2022, 7(2): 6-10.
[2]	刘栋, 王帅迪, 冯明男, 黄顺星, 李硕, 杜霄鹏, 刘亚欧, 丁金立. 新型冠状病毒肺炎防控常态化情况下隔离区方舱CT的临床应用探讨[J]. 新发传染病电子杂志, 2022, 7(2): 11-14.
[3]	蒋学美, 宋艳, 陈艳, 何利, 邵蔚. 新型冠状病毒肺炎疫情常态化下消毒供应中心的防控策略[J]. 新发传染病电子杂志, 2022, 7(2): 15-18.
[4]	牛翊霖, 张纯, 曹雯煜, 刘旭玲, 吴清华, 刘滢芳, 张宝, 赵卫. 年龄因素对新型冠状病毒易感性的影响[J]. 新发传染病电子杂志, 2022, 7(2): 19-24.
[5]	江苏省研究型医院学会感染与炎症放射学专业委员会, 江苏省放射诊断专业质量控制中心, 江苏省医学会放射学分会感染病学组. 江苏省新型冠状病毒肺炎影像学检查、诊断及防控规范专家共识（2022第二版）[J]. 新发传染病电子杂志, 2022, 7(2): 79-88.
[6]	廖康生, 卢洪洲. 新型冠状病毒奥密克戎变异株的研究进展：对其科学防控措施的启示[J]. 新发传染病电子杂志, 2022, 7(1): 1-5.
[7]	覃亚勤, 罗凤, 黎彦君, 韦征. 艾滋病合并恶性肿瘤住院患者疾病谱分析[J]. 新发传染病电子杂志, 2022, 7(1): 39-42.
[8]	于埼, 宋艳, 刘思聪, 王梦梦, 张爱玲. 非感染科抗疫支援护士医院感染防控知信行的调查分析[J]. 新发传染病电子杂志, 2022, 7(1): 60-65.
[9]	芦鸿曦, 刘刚, 陈歆. 世界卫生组织关注的新型冠状病毒变异株病毒学特征分析[J]. 新发传染病电子杂志, 2022, 7(1): 88-91.
[10]	吴伟刚, 杨智, 欧鹏程, 曾芙蓉, 吕小青, 王佳露, 郭建伟, 吴诗品, 杨桂林. 及时更新的诊疗方案对新型冠状病毒肺炎疫情防控的临床价值[J]. 新发传染病电子杂志, 2022, 7(1): 100-103.
[11]	詹香明, 卢洪洲. 新型冠状病毒肺炎对全球HIV感染者影响的研究进展[J]. 新发传染病电子杂志, 2021, 6(4): 356-360.
[12]	卢春容, 房宏霞, 陆普选, 季乐财. WHO 2021年全球结核病报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2021, 6(4): 368-372.
[13]	甘清鑫, 刘晋新, 杨彦鸿, 胡天丽, 张烈光, 黄德扬, 李美瑜. 白细胞介素-6与新型冠状病毒B.1.617.2变异株引起肺损伤相关性的人工智能定量分析[J]. 新发传染病电子杂志, 2021, 6(3): 172-176.
[14]	卢茜, 高世同, 刘渠, 张仲明. 广东省1例输入性新型冠状病毒肺炎合并卵形疟病例调查分析与诊断[J]. 新发传染病电子杂志, 2021, 6(3): 177-180.
[15]	郭津含, 陈建林, 葛岚岚, 万浩强, 杨天庆, 缪雨阳, 肖凌云, 凌云志, 曾小斌. 金银花对轻型新型冠状病毒肺炎治疗的药理价值[J]. 新发传染病电子杂志, 2021, 6(3): 181-188.